Member Info for volcano

BRIEF-Lamprell receives debt waivers Wed, 2nd Jan 2013 09:24 LONDON, Jan 2 (Reuters) - Lamprell PLC: * Received the necessary waivers from its various lenders with respect to its existing debt facilities * Working capital position of the company has improved significantly * Ended the year with a net cash position in the region of US$100 million * The revenue levels will reduce in the early part of 2013 * Caspian sea jack-up project - has successfully launched the rig into the water * Recently been awarded a further North Sea related project valued at

i have been telling everyone about EXI start paying off next quarter to be in the FTSE 250 i hope .

excellent trading share

it could bounce soon .

i will double my investment but EXI got a long way to go yet to reach all time high of 480p. with this type of news i can see them get there. Exillon Energy plc November Production Report 3 December 2012 3 December 2012 - Exillon Energy plc (EXI.LN), a London Premium listed independent oil producer with assets in two oil-rich regions of Russia, Timan-Pechora ("Exillon TP") and West Siberia ("Exillon WS"), is pleased to announce unaudited production data for the month of November 2012 ("the Period"). · Our average daily production[1] was 15,427 bbl/day during the period. · Average daily production for Exillon TP was 3,854 bbl/day, and for Exillon WS it was 11,573 bbl/day during the period. · Our peak daily production[2] was 16,196 bbl/day during the period. We expect to make the December production announcement by 5 January 2013.

i need to break even

i do not know about £5 but £3 is possible ,they are £6.5b company already . i do hold shares in both but still loosing money .ohhh one day .

anyone any idea why the price collapse today 120p now

Russian gold miner Highland Gold (HGM) kept good on one of its promises in the first half - increasing gold production to 101,900 ounces from 93,057 ounces in the same period last year. This means the company remains on track to produce between 200,000 and 215,000 ounces of gold in 2012, and, with the shares up 13 per cent on our buy tip since July, and quantitative easing in the US supporting a bullish gold price environment, there should be further upside to come. Coupled with a 5 per cent rise in the average price of gold received, the production increase resulted in a minor revenue boost and another healthy interim dividend for Highland in the first half. Nevertheless, operating cash costs soared to $804 (£496) an ounce from $531 an ounce in the same period last year - which is also well up on the $594 per ounce achieved in full-year 2011. Management blamed the greater-than-expected rise on higher waste stripping volumes at the ageing MNV mine as well as lower-grade ore being processed at both MNV and the Novo mine. Prior to these results, Numis Securities forecast full-year EPS of 34¢ (2011: 31.9¢). HIGHLAND GOLD (HGM) ORD PRICE: 125p MARKET VALUE: £406m TOUCH: 124-125p 12-MONTH HIGH: 205p LOW: 94p DIVIDEND YIELD: 3.8% PE RATIO: 8 NET ASSET VALUE: 227¢ NET CASH: $110m Half-year to 30 Jun Turnover ($m) Pre-tax profit ($m) Earnings per share (¢) Dividend per share (p)** 2011 158 85.1 21.6 5.00 2012 161 57.3 13.9 4.80 % change +2 -33 -36 -4 Ex-div: 26 Sep Payment: 19 Oct £1=$1.62 **Dividend includes special dividend of 2.5p a share in 2011, and 4.8p in 2012 SHARE TIP UPDATE: When we advised buying Highland shares in mid-July at 111p it was because they offered an attractive way of playing a rising gold price on the back of extra doses of quantitative easing by central banks. This is still the case and with the gold price - currently $1776/oz - heading back up towards its all-time high of $1,920/oz - it is likely to send Highland’s shares up with it. Buy.

2nd Resistance Point 140.040 1st Resistance Point 138.270 Last Price 136.500 1st Support Level 133.490 2nd Support Level 130.480 strong buy

H1 2012 H1 2011 Growth AER CER Revenue £371.6m £335.0m +10.9% +9.8% Adjusted Profit before tax £12.0m £34.0m -64.7% -68.2% Profit before tax £9.9m £28.6m -65.4% -69.6% Adjusted operating profit margin 4.3% 11.5% -720 bps Basic earnings per share 5.9p 17.9p -67.0% Adjusted diluted earnings per share 7.0p 20.9p -66.5% Interim dividend per share 4.5p 4.5p -

Barclays raises Yule Catto price target to 256p from 255p; rating overweight

UPDATE 1-Samsung buys chipmaker CSR's handset technology Tue, 17th Jul 2012 08:11 LONDON, July 17 (Reuters) - British chip firm CSR has sold its mobile phone connectivity and l ocation technology to Samsung for $310 million in cash in a deal that boosts the South Korean company's patent portfolio. Samsung will also invest $34.4 million in buying a 4.9 percent stake in CSR at a price of 223 pence a share, CSR said in a statement on Tuesday. CSR Chief Executive Joep van Beurden said the deal unlocked value for shareholders, and would enable the company to focus on areas where it had a leading market position, such as audio, automotive, indoor location, imagining and bluetooth. 'I believe that under Samsung's ownership the handset operations will be in a better position to prosper in the global handset market,' he said. CSR's position in handsets had faltered in recent years because its chips had been included in few fast-selling smartphones, although it was trying to make up lost ground with a new wi-fi bluetooth combination chip. It has had more success in its audio technology, where its technology is used in high-end headphones such as those made by Sennheiser and the 'Beats by Dr Dre' range. The British company said it would return up to $285 million to shareholders following the deal, which is expected to complete in the fourth quarter.

i used to trade this few years ago at 10p

i said it before it will go down to 5p and some people said i was mad i rest my case .

yes i could had some for instance IC

this will be £2 soon.

here we go again

maybe turning keep eye on it today

Inhaled medicines specialist Vectura spent last year watching its development partner Novartis amassing the Phase III data needed to win regulatory approval for its two lead chronic obstructive pulmonary disorder (smoker's cough) products NVA237 and QVA149. That process is well advanced and Novartis has enough data to get the products in front of regulators within the next couple of years to provide the shares with some much needed momentum. The first of these decisions will be in Europe later this year for NVA237. If, as expected, the product is approved for prescription in the EU, this will trigger a further $10m (£6.25m) milestone payment for Vectura. Management reckons that so far NVA237 has returned four times the company's initial investment in milestone payments alone. The testing programme for US regulatory approval is taking longer because of extra data requested by the FDA, consequently product filings aren't expected before 2014. However, the company did earn $2m from a new collaboration on VR315, the supposed generic version of GlaxoSmithKline's blockbuster drug Advair, from a mystery big pharma partner with a US subsidiary. In the meantime, costs are under control and research and development costs fell 13 per cent to £32.8m for the year. Cannacord Genuity expects the current year loss per share will be cut from 4.4p to 2.6p and has a sum-of-the-parts valuation of 114p. VECTURA (VEC) ORD PRICE: 66p MARKET VALUE: £219m TOUCH: 65-66p 12-MONTH HIGH: 107p LOW: 50p DIVIDEND YIELD: nil PE RATIO: na NET ASSET VALUE: 42p* NET CASH: £75.5m Year to 31 Mar Turnover (£m) Pre-tax profit (£m) Earnings per share (p) Dividend per share (p) 2008 25.2 -21.4 -6.1 nil 2009 31.2 -19.6 -5.2 nil 2010 40.1 -13.8 -3.2 nil 2011 42.9 -13.3 -2.7 nil 2012 33.0 -13.2 -1.3 nil % change -23 - - - *Includes intangible assets of £73m, or 22p a share TIP UPDATE: More clarity on US regulatory timings will help sentiment this year and, with plenty of cash to run its operations, Vectura's current share price still looks a good entry point. Buy.